Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world

Francisco Daniel Epelde Gonzalo

Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world

Departament de Medicina

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

Idioma original	Anglès
Revista	European Journal of Heart Failure
Estat de la publicació	Publicada - 2019

Com citar-ho

@article{7145e61cc8b94772aeab50924297106f,

title = "Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world",

author = "{Epelde Gonzalo}, {Francisco Daniel}",

year = "2019",

language = "English",

journal = "European Journal of Heart Failure",

issn = "1388-9842",

}

Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world. / Epelde Gonzalo, Francisco Daniel.
In: European Journal of Heart Failure, 2019.

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

TY - JOUR

T1 - Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world

AU - Epelde Gonzalo, Francisco Daniel

PY - 2019

Y1 - 2019

M3 - Article

SN - 1388-9842

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

ER -